Form 10 Explorer
10-Q
Quarterly Report
AIM IMMUNOTECH INC.

AIM

NYSEAMER

CIK: 946644

File #: 001-27072

Period End: Mar 31, 2024

Fiscal Year: 2024

View on EDGAR
Balance Sheet
36 line items · 2 periods
XBRL
ItemMar 31, 2024Dec 31, 2023
ASSETS
Current assets:
Cash and Cash Equivalents
3,295,0005,439,000
Cash and Cash Equivalents
7,647,0007,631,000
Accounts Receivable
1,184,000
Other Non-Operating Current Assets
364,000302,000
Total current assets
11,306,00014,556,000
Property, Plant and Equipment
118,000127,000
Operating Lease Right-of-Use Asset
763,000697,000
Intangible Assets
2,314,0002,313,000
Patents
2,201,0002,197,000
Trademarks
113,000116,000
Other Non-Operating Non-Current Assets
1,688,0001,688,000
Total assets
16,189,00019,381,000
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts Payable
6,567,0006,443,000
Other Current Liabilities
1,446,0001,986,000
Operating Lease Liability, Current
240,000223,000
Short-Term Debt
1,623,000
Total current liabilities
9,876,0008,652,000
Long-term liabilities:
Operating Lease Liability, Non-Current
537,000495,000
Long-Term Debt
950,000
Total liabilities
11,363,0009,147,000
Stockholders’ equity:
Series B Convertible Preferred Stock
689,000689,000
Total Stockholders' Equity
50,00049,000
Total Stockholders' Equity
419,412,000419,004,000
Total Stockholders' Equity
(415,325,000)(409,508,000)
Total stockholders’ equity
4,826,00010,234,000
Series B Preferred Stock - Preferred Stock
689,000689,000
Common Stock
50,00049,000
Additional Paid-in Capital
419,412,000419,004,000
Retained Earnings
(415,325,000)(409,508,000)
Total liabilities and stockholders’ equity
16,189,00019,381,000